Quantcast

ReBuilder Medical Technologies, Inc. To Provide Physicians With Professional Version of Its Proven ReBuilder System; Sales Expected to Increase By 14%

October 17, 2007

CHARLES TOWN, W.V., Oct. 17 /PRNewswire/ — ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) announced to its board of directors today that the company’s engineering staff has completed the design of a professional, physician-use version of its ReBuilder System(R) for the treatment of diabetic peripheral neuropathy. In addition to treating this debilitating condition, the new ReBuilder System(R) model possesses diagnostic capabilities. Each time the physician uses the system, ReBuilder Medical Technologies, Inc. will receive a portion of the fee.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

The Physician’s 2408 model will include ReBuilder’s proven electronic treatment for neuropathy, plus a non-invasive neurological evaluation capability. The 2408 model will measure the electrical activity of muscles and nerves non-invasively, thereby determining if there is nerve damage, the extent of the damage and, in some cases, its cause.

“The redesign of the ReBuilder series represents a dramatic leap forward in the treatment and evaluation of neuropathy,” said Dr. David B. Phillips, ReBuilder Medical President.

“We have had wonderful consumer market acceptance of our consumer model 2406 and earlier models,” reports David B. Phillips, Ph.D., CEO of ReBuilder Medical Technologies, Inc. “Many of our retail Internet customers have taken it upon themselves to show their physician this new technology, and shared with their doctors the complete resolution of their symptoms. As a result of these successes,” said Phillips, “physicians have been ordering the consumer unit for use in their offices, and insisting that we develop a professional unit that offers both stronger treatment and diagnostic capabilities. We are simply responding to that request.”

About ReBuilder Medical Technologies, Inc.:

ReBuilder Medical Technologies, Inc. is a manufacturer of medical devices and innovative technologies founded by world-renowned medical device inventor David B. Phillips, Ph.D. The company’s flagship product is its FDA registered ReBuilder System(R), used for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) that depend on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery-powered medical product that provides a unique, non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.

ReBuilder Medical Technologies, Inc. also manufactures the Phillips Molluscum Treatment System(TM) for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum pathogen without side effects. The company is currently performing research and development on a number of other products as well.

ReBuilder Medical Technologies, Inc. is located in Charles Town, WV. CEO, Dr. David Phillips, Ph.D. is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System, which is used for the early detection of breast cancer, and the AcuPen, a hand-held device that provides the benefits of acupuncture without the use of needles.

More information on ReBuilder Medical Technologies, Inc. and its products can be found at: http://www.rebuildermedical.com/.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words “estimate,”"anticipate,”"expect,”"believe,” and similar expressions are intended to be forward-looking statements.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.com

ReBuilder Medical Technologies, Inc.

CONTACT: Daena Carter of ReBuilder Medical Technologies, Inc.+1-304-725-2202




comments powered by Disqus